KineMed, Inc., a platform-based drug development and advanced medical diagnostics company, announced today that breakthrough results from two new product programs were presented at the American Diabetes Association's 65th Annual Scientific Sessions held in San Diego. In a poster presentation entitled, "The Deuterated-Glucose Disposal Test (2H-GDT): A Sensitive, High-Throughput Measure of Insulin Resistance and the Adequacy of Pancreatic Beta-Cell Compensation in vivo", the Company presented data from a new study comparing the KineMarker(TM) insulin resistance test with the traditional hyperinsulinemic-euglycemic glucose clamp method in lean individuals and obese subjects with Metabolic Syndrome. The study was designed to demonstrate the reliability of the assay in measuring insulin resistance in humans. Measurements taken in 20 subjects showed a tight correlation between the KineMarker(TM) and clamp data (R2 >0.90). This technique was also shown to detect both genetic and diet-induced insulin resistance in animal models, as well as the response to insulin-sensitizing agents and strain and model differences in beta-cell compensation to insulin resistance.

Additionally, in a poster entitled, "In Vivo Measurement of Pancreatic Beta-cell Proliferation with Heavy Water (2H2O)", the Company presented data in several animal models demonstrating the ability of KineMed's assay to identify and monitor, for the first time, the pancreatic beta-cell response to insulin resistance. Insulin resistance progresses to type 2 diabetes when failure of pancreatic beta-cell compensation occurs (termed "pancreatic exhaustion"). There has been no previous method for detecting early signs of failing pancreatic beta-cell compensation.

In this second presentation, Company researchers reported that stable isotope labeling with mass spectrometric analysis showed that the injured pancreas has the ability to generate new beta cells and that this technique was applied to study beta-cell proliferation in genetic obesity. Beta-cell proliferation was measured in two animal models sharing the same genetic defect but with different propensities towards diabetes. Lower beta-cell proliferation rates were shown in the diabetic models compared to fatty non-diabetic models. This difference in the ability to make new pancreatic beta-cells may contribute to diabetes development. The availability of this new technology will allow high-throughput in vivo screening for agents that affect pancreatic regeneration.

David Fineman, President and CEO of KineMed, commented, "This is the first time that drug developers will have such a complete program to characterize glucose homeostatic status and susceptibility to developing type 2 diabetes. Our results show that KineMed's KineMarkers allow pancreatic compensation and beta-cell regeneration to be measured at the same time that the degree of insulin resistance is measured. Applications include development of new drugs targeting pre-diabetes, diabetes and the metabolic syndrome."

KineMed KineMarker(TM) Product Programs in Diabetes
KineMed's proprietary in vivo KineMarker(TM) assays provide new, sensitive and high-throughput measures of several key metabolic pathways involved in the pathogenesis and treatment of diabetes and other metabolic disorders. These assays can be used in clinical as well as pre-clinical settings.

KineMed's insulin resistance KineMarker(TM) is much easier to apply and less labor-intensive than the traditional hyperinsulinemic-euglycemic glucose clamp method, which is the current "gold-standard" in the field. Clinical trial efficiency and patient comfort are thereby improved considerably. Subjects drink a specially labeled glucose-containing drink, and a small amount of blood (i.e., a few drops) is taken after 2-3 hours have passed.

KineMed's second product program in diabetes offers a pre-clinical measure of pancreatic beta-cell proliferation. This assay provides a new, less labor-intensive, more sensitive and much more highly reproducible measure of insulin-secreting cell (pancreatic beta-cell) regeneration. New drug candidates that target the regeneration of pancreatic beta-cells are being developed, but previous methods could only measure pancreatic beta-cell mass by histology rather than the true regeneration rate of beta-cells, as KineMed's test achieves.

About KineMed, Inc.
KineMed, Inc. provides a proprietary set of tools for measuring the dynamics of molecular and cellular response to drugs in the intact organism, both in animals and humans. KineMed's technology is ideally suited to enable the discovery of entirely new, unanticipated uses for compounds (an approach called repurposing or repositioning) by screening for activity in vivo across a wide variety of disease states. The breadth of therapeutic targets covered by KineMarker(TM) assays allows high-throughput screening in conditions beyond those typically evaluated. KineMed's technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, and diseases of inflammation and neurodegeneration. For further information about KineMed, please visit: http://www.kinemed.com/.

For further information about KineMed, please visit: http://www.kinemed.com

CONTACT:
Lisa Misell, Ph.D. Director of Business Development of KineMed, +1-510-655-6525, ext.117,
or Media: Justin Jackson, Burns McClellan, +1-212-213-0006, jjackson@burnsmc.com for KineMed, Inc.